argenx reports 54 percent VYVGART growth for argenx stock

Published on 10/26/2026 at 15:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

VYVGART sales reached USD 1.72 billion in the third quarter. argenx stock costs EUR 784.00 on October 26, 2026, 0.03 percent below the Xetra close.

argenx adds growth but costs rise

argenx reported USD 1.72 billion in VYVGART product sales for the third quarter of 2026, up 54.00 percent year over year.
Total operating income reached USD 1.75 billion, while operating profit rose to USD 486.00 million and the operating margin was 28.00 percent.
argenx stock was at EUR 784.00 at Lang & Schwarz on October 26, 2026 at 3:41 p.m. CEST, 0.03 percent below the Xetra close of October 23, 2026 at EUR 784.20.

Argenx, NL0010832176, Illustration mit AI erstellt.

argenx (ISIN NL0010832176) generated USD 1.72 billion in VYVGART product sales in the third quarter of 2026, up 54.00 percent from the same period of 2025. The company also reported total operating income of USD 1.75 billion and operating profit of USD 486.00 million, according to the argenx release dated October 22, 2026.

VYVGART remains the growth engine

The latest quarter extends the commercial expansion already visible in argenx's lead franchise. VYVGART product sales increased from USD 1.13 billion in the third quarter of 2025 to USD 1.72 billion in the third quarter of 2026, a USD 594.00 million increase.

Total operating income climbed from USD 1.15 billion to USD 1.75 billion over the same period. Profit rose from USD 344.00 million to USD 506.00 million, while basic profit per share increased from USD 5.61 to USD 8.07.

Forte costs weigh on the margin

The main counterweight is expense growth. Total operating expenses reached USD 1.27 billion in the third quarter of 2026, compared with USD 805.00 million a year earlier. Selling and general administrative expenses included approximately USD 150.00 million of acquisition-related costs linked to Forte Biosciences.

That cost explains why the 28.00 percent operating margin deserves attention even as revenue expands. The company said combined research and development plus selling and general administrative expenses are expected to be approximately USD 4.00 billion for fiscal year 2026, including Forte-related costs.

Stock reaction stays restrained

The earnings update adds a new operating picture to the clinical setback covered earlier in October: commercial growth is strong, but integration costs make the near-term earnings quality more important. argenx also expects Phase 3 empasiprubart results in multifocal motor neuropathy in December 2026, according to the company release.

argenx stock was trading at EUR 784.00 at Lang & Schwarz on October 26, 2026 at 3:41 p.m. CEST, minus 0.03 percent versus the Xetra close of October 23, 2026 at EUR 784.20. The further course of trading is shown by the continuously updated real-time quote of argenx stock.